Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
C E SharonG N TortorelloK L MaA C HuangX XuL R GilesS McGettiganK KreiderL M SchuchterA J MathewR K AmaravadiP A GimottyJ T MiuraG C KarakousisT C MitchellPublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)